Purpose Patients admitted to intensive care unit (ICU) with Klebsiella pneumoniae infections
are characterized by high mortality. The aims of the present study were to investigate the …

In the present study, population pharmacokinetic (PK) analysis was performed based on
meropenem data from a prospective study conducted in 114 critically ill patients with a wide …

Abstract Background Several population pharmacokinetic (PopPK) models for meropenem
dosing in ICU patients are available. It is not known to what extent these models can predict …

Background and objective: Meropenem is a carbapenem antibacterial frequently prescribed
for the treatment of severe infections in critically ill patients, including those receiving …

Background: The aim of this study was to conduct a population pharmacokinetic (PK)
analysis of meropenem and to explore the optimal dosing strategy for meropenem in …

Objectives The use of extended intermittent infusion (EII) or continuous infusion (CI) of
meropenem is recommended in intensive care unit (ICU) patients, but few data comparing …

Background The primary objective of this study was to develop a population
pharmacokinetic model of meropenem, based on the population of critically ill adult patients …

Purpose To develop a meropenem population pharmacokinetic model in critically ill patients
with particular focus on optimizing dosing regimens based on renal function. Methods …

Background Meropenem is commonly used in the ICU to treat gram-negative infections. Due
to various pathophysiological changes, critically ill patients are at higher risk of having …

Purpose In critically ill patients treated with meropenem, the proposed pharmacokinetics/
pharmacodynamics (PK/PD) efficacy index is to keep the free drug concentration 4–5 times …